Curevac N.V. (CVAC)

$5.45 +0.06 (1.11%)
Market Cap 1.22B
Revenue (ttm) 579.12M
Net Income (ttm) 175.50M
EPS (ttm) N/A
PE Ratio 5.61
Forward PE N/A
Profit Margin 30.30%
Debt to Equity Ratio 0.00
Volume 531,900
Avg Vol 546,652
Day's Range N/A - N/A
Shares Out 224.34M
Stochastic %K 100%
Beta 2.51
Analysts Hold
Price Target $4.30

Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytopl...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 7071 9883 0
Address:
Friedrich-Miescher-Strasse 15, Tübingen, Germany
DocPharm
DocPharm Oct. 4 at 4:08 PM
$BNTX bought the other 💎 $CVAC for mRNA patents (waiting for conversion) Will they or $PFE buy the gem $ABUS / ROIV/ Genevant for the LNP patents ? Very plausible
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 5:50 PM
$CVAC Really good write-up that perfectly summarizes CVAC's present situation. So if you want to bring your CVAC knowledge up to date or just discover CVAC, this is required reading. https://beyondspx.com/quote/CVAC/analysis/curevac-s-mrna-evolution-from-pioneer-to-integrated-powerhouse-nasdaq-cvac
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:08 PM
$PRAA Pra Group Trades: 39 | Total $: 20.4 K | 3.08 × 90-Day Avg $: 6.6 K | Call $: 450 | Put $: 20 K | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $GENC Gencor Industries Trades: 4 | Total $: 450 | 0.28 × 90-Day Avg $: 1.6 K | Call $: 450 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $CVAC Curevac Trades: 3 | Total $: 450 | 0.04 × 90-Day Avg $: 10.5 K | Call $: 450 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $SF Stifel Financial Trades: 1 | Total $: 450 | 0.02 × 90-Day Avg $: 22.8 K | Call $: 450 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
DocPharm
DocPharm Aug. 18 at 7:29 PM
$CVAC still have a few thousand left - when is the conversion? And how many for how many TYIA
0 · Reply
DaxCo
DaxCo Aug. 8 at 6:39 AM
$ABUS $BNTX $MRNA $CVAC
1 · Reply
taxplanr
taxplanr Aug. 6 at 2:25 AM
HHS Sec Kennedy BARDA canceling 22 malignantRNA programs $BNTX $MRNA $PFE $CVAC https://truthsocial.com/@seckennedy/114978386245597771
0 · Reply
Jbjb90
Jbjb90 Jul. 24 at 2:12 PM
$SANA $PBM $LXRX added to all three today, sold out of $CVAC
0 · Reply
Jbjb90
Jbjb90 Jul. 20 at 2:31 AM
$CVAC Is this buyout a done deal or is there any chance someone comes in and makes a better offer? I made the mistake of selling my H E Equipment shares when united rental bought them out and then Herc swooped in at the last minute and made a better offer so i missed out on some profits.
1 · Reply
Jordand91
Jordand91 Jul. 11 at 6:55 PM
$NVAX go and check out $CVAC has a lot more promise than nova. Actually everything at this point has more promise than nova
3 · Reply
taxplanr
taxplanr Jul. 11 at 1:10 PM
$BNTX $MRNA $CVAC $BMY there is no future for malignantRNA in medicine
1 · Reply
Latest News on CVAC
CureVac: The Hidden Value Of The mRNA Wallet

Oct 1, 2025, 5:26 AM EDT - 4 days ago

CureVac: The Hidden Value Of The mRNA Wallet

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

Aug 15, 2025, 7:50 AM EDT - 7 weeks ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 2 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

BNTX PFE

CureVac Announces Voting Results of General Meeting

Jun 24, 2025, 4:35 PM EDT - 3 months ago

CureVac Announces Voting Results of General Meeting

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

Jun 12, 2025, 12:05 PM EDT - 4 months ago

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

BA ORCL

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

Jun 12, 2025, 11:07 AM EDT - 4 months ago

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BNTX

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

Jun 12, 2025, 7:11 AM EDT - 4 months ago

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

BNTX

BioNTech to acquire CureVac in $1.25 billion all-stock deal

Jun 12, 2025, 7:03 AM EDT - 4 months ago

BioNTech to acquire CureVac in $1.25 billion all-stock deal

BNTX

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

May 20, 2025, 7:15 AM EDT - 4 months ago

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

May 15, 2025, 4:45 PM EDT - 5 months ago

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

Apr 10, 2025, 12:59 PM EDT - 6 months ago

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Apr 10, 2025, 7:30 AM EDT - 6 months ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

Apr 8, 2025, 7:25 AM EDT - 6 months ago

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Apr 7, 2025, 7:15 AM EDT - 6 months ago

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

Mar 28, 2025, 12:45 PM EDT - 6 months ago

CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit

BNTX

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

Mar 28, 2025, 8:58 AM EDT - 6 months ago

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

European Patent Office declares CureVac mRNA patent valid

Mar 27, 2025, 6:22 PM EDT - 6 months ago

European Patent Office declares CureVac mRNA patent valid

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

Mar 27, 2025, 4:30 PM EDT - 6 months ago

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

Feb 18, 2025, 7:15 AM EST - 8 months ago

CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

Jan 8, 2025, 4:55 PM EST - 9 months ago

CureVac: Latest GBM Data Bodes Well For Next Program Check Point

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 3:08 PM EST - 11 months ago

CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Nov 12, 2024, 7:20 AM EST - 11 months ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Nov 7, 2024, 7:30 AM EST - 11 months ago

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Nov 4, 2024, 7:20 AM EST - 11 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

CureVac to Present at the 12th International mRNA Health Conference

Nov 4, 2024, 7:15 AM EST - 11 months ago

CureVac to Present at the 12th International mRNA Health Conference

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 28, 2024, 8:10 AM EDT - 1 year ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

Oct 8, 2024, 5:50 AM EDT - 1 year ago

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

BNTX PFE

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Sep 13, 2024, 8:15 AM EDT - 1 year ago

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Sep 12, 2024, 7:15 AM EDT - 1 year ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Sep 9, 2024, 7:15 AM EDT - 1 year ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Aug 15, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Aug 15, 2024, 7:20 AM EDT - 1 year ago

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Aug 15, 2024, 7:15 AM EDT - 1 year ago

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Jul 11, 2024, 7:15 AM EDT - 1 year ago

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

Jul 3, 2024, 10:18 AM EDT - 1 year ago

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines

GSK

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

Jul 3, 2024, 7:53 AM EDT - 1 year ago

CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines

GSK

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

Jul 3, 2024, 2:40 AM EDT - 1 year ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Jul 3, 2024, 2:40 AM EDT - 1 year ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

GSK buys full rights to make COVID, influenza vaccines from CureVac

Jul 3, 2024, 2:26 AM EDT - 1 year ago

GSK buys full rights to make COVID, influenza vaccines from CureVac

GSK

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

Apr 24, 2024, 3:12 PM EDT - 1 year ago

CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 1 year ago

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Apr 24, 2024, 7:20 AM EDT - 1 year ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

Apr 18, 2024, 7:15 AM EDT - 1 year ago

CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

Apr 16, 2024, 7:15 AM EDT - 1 year ago

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Apr 4, 2024, 7:15 AM EDT - 1 year ago

CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

CureVac stock gains as COVID vaccine candidates show promise

Jan 5, 2024, 7:59 AM EST - 1 year ago

CureVac stock gains as COVID vaccine candidates show promise

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Jan 5, 2024, 7:30 AM EST - 1 year ago

CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

DocPharm
DocPharm Oct. 4 at 4:08 PM
$BNTX bought the other 💎 $CVAC for mRNA patents (waiting for conversion) Will they or $PFE buy the gem $ABUS / ROIV/ Genevant for the LNP patents ? Very plausible
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 5:50 PM
$CVAC Really good write-up that perfectly summarizes CVAC's present situation. So if you want to bring your CVAC knowledge up to date or just discover CVAC, this is required reading. https://beyondspx.com/quote/CVAC/analysis/curevac-s-mrna-evolution-from-pioneer-to-integrated-powerhouse-nasdaq-cvac
0 · Reply
highnihilism
highnihilism Oct. 1 at 12:08 PM
$PRAA Pra Group Trades: 39 | Total $: 20.4 K | 3.08 × 90-Day Avg $: 6.6 K | Call $: 450 | Put $: 20 K | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $GENC Gencor Industries Trades: 4 | Total $: 450 | 0.28 × 90-Day Avg $: 1.6 K | Call $: 450 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $CVAC Curevac Trades: 3 | Total $: 450 | 0.04 × 90-Day Avg $: 10.5 K | Call $: 450 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $SF Stifel Financial Trades: 1 | Total $: 450 | 0.02 × 90-Day Avg $: 22.8 K | Call $: 450 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
DocPharm
DocPharm Aug. 18 at 7:29 PM
$CVAC still have a few thousand left - when is the conversion? And how many for how many TYIA
0 · Reply
DaxCo
DaxCo Aug. 8 at 6:39 AM
$ABUS $BNTX $MRNA $CVAC
1 · Reply
taxplanr
taxplanr Aug. 6 at 2:25 AM
HHS Sec Kennedy BARDA canceling 22 malignantRNA programs $BNTX $MRNA $PFE $CVAC https://truthsocial.com/@seckennedy/114978386245597771
0 · Reply
Jbjb90
Jbjb90 Jul. 24 at 2:12 PM
$SANA $PBM $LXRX added to all three today, sold out of $CVAC
0 · Reply
Jbjb90
Jbjb90 Jul. 20 at 2:31 AM
$CVAC Is this buyout a done deal or is there any chance someone comes in and makes a better offer? I made the mistake of selling my H E Equipment shares when united rental bought them out and then Herc swooped in at the last minute and made a better offer so i missed out on some profits.
1 · Reply
Jordand91
Jordand91 Jul. 11 at 6:55 PM
$NVAX go and check out $CVAC has a lot more promise than nova. Actually everything at this point has more promise than nova
3 · Reply
taxplanr
taxplanr Jul. 11 at 1:10 PM
$BNTX $MRNA $CVAC $BMY there is no future for malignantRNA in medicine
1 · Reply
taxplanr
taxplanr Jul. 9 at 2:20 PM
$BNTX $MRNA $CVAC $NVAX only sales plan https://jonfleetwood.substack.com/p/pegasus-uk-to-run-largest-ever-national
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 8 at 5:05 AM
Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma $MRNA $NVAX $CVAC $GSK $TRAW https://stocktwits.com/news/equity/markets/cooling-us-bird-flu-wave-removes-tailwind-for-moderna-novavax-cure-vac-traws-pharma/chFvLokR5Qy
1 · Reply
justiceforb_85
justiceforb_85 Jul. 3 at 8:05 PM
$CVAC when does the deal close?
0 · Reply
taxplanr
taxplanr Jun. 30 at 2:31 PM
$MRNA $BNTX $CVAC $BMY please let everyone know about the Ivermectin Menbendazole Breast cancer treatment break throughs https://www.onedaymd.com/2024/08/ivermectin-in-stage-4-cancers-2024.html
0 · Reply
taxplanr
taxplanr Jun. 26 at 7:14 PM
Ivermectin and Menbendazole Glioblastoma testimonial after 5 months $BNTX $CVAC $MRNA $BMY https://makismd.substack.com/p/ivermectin-and-mebendazole-testimonial-52f?utm_source=post-email-title&publication_id=1385328&post_id=166913331&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
2 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jun. 26 at 3:32 PM
$CVAC UBS Downgrades CureVac to Neutral, Lowers Price Target to $5.5
0 · Reply
taxplanr
taxplanr Jun. 26 at 1:47 PM
$BNTX $MRNA $PFE $CVAC American Academy of Pediatrics throws the CDC vaccine guidelines under the bus Who will people listen to? https://karenkingston.substack.com/p/american-academy-of-pediatrics-discredits?utm_source=post-email-title&publication_id=1103773&post_id=166846433&utm_campaign=email-post-title&isFreemail=false&r=18m8lm&triedRedirect=true&utm_medium=email
1 · Reply
taxplanr
taxplanr Jun. 26 at 1:43 PM
CDC picked apart and exposed at first ACIP meeting with new members $BNTX $MRNA $PFE $CVAC https://childrenshealthdefense.org/defender/acip-advisers-cdc-covid-vaccine-safety-claims/?utm_source=luminate&utm_medium=email&utm_campaign=defender&utm_id=20250625
0 · Reply
taxplanr
taxplanr Jun. 25 at 6:22 PM
$BNTX $MRNA $PFE $CVAC “Our findings suggest possible indirect transmission of ingredients or products of the COVID-19 vaccines, presumably through shedding, from people who received one or more of the COVID-19 injections." It just sounds like a bioweapon https://ijvtpr.com/index.php/IJVTPR/article/view/113
0 · Reply
taxplanr
taxplanr Jun. 25 at 4:05 PM
Did you know John Hoppkins University owns the patent for treating colon cancer with Menbendazole? $BNTX $MRNA $CVAC $BMY https://patents.google.com/patent/US11110079B2/en
0 · Reply
taxplanr
taxplanr Jun. 25 at 1:40 PM
$CVAC did 50% more volume than $BNTX did yesterday ... reminds me of that line about Will Rogers
0 · Reply
taxplanr
taxplanr Jun. 24 at 1:48 PM
The $BNTX $CVAC deal is another scam for $PFE to off load liability onto useful retail idiots
0 · Reply